Slovenian study aims to predict who benefits from melanoma immunotherapy

NCT ID NCT07422779

Recruiting now Knowledge-focused Sponsor: Institute of Oncology Ljubljana Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 100 people in Slovenia with advanced melanoma who are receiving first-line immunotherapy drugs like pembrolizumab, nivolumab, or ipilimumab. Researchers want to see how well these treatments work and whether a marker called PD-L1 in tumors or blood can predict response. The goal is to improve treatment decisions for future patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab, Nivolumab, Ipilimumab
What this could lead to: If successful, this could help doctors better predict which patients will respond to immunotherapy for metastatic melanoma.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma skin cancer skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MELANOMA SKIN CANCER

Contacts and locations

Locations

Institute of Oncology Ljubljana
RECRUITING

Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.